PD24-06 PROSTATIC ARTERY EMBOLIZATION TO TREAT GROSS HEMATURIA ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 3-YEAR OUTCOMES

  • Ayyagari* R
  • Powell T
  • Chapiro J
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

INTRODUCTION AND OBJECTIVES: Prostatic artery embolization (PAE) is a minimally invasive angiographic procedure used to treat hematuria caused by benign prostatic hyperplasia (BPH). However scarce outcomes data exist on PAE for gross hematuria. This study presents medium-term safety and efficacy data for PAE to treat gross hematuria caused by BPH. METHODS: 66 patients undergoing PAE in the setting of gross hematuria from December 2013 through August 2018 were reviewed retrospectively. Patients were included if cystoscopy found a large bleeding prostate and upper tract evaluation was negative. Patients were excluded for other hematuria sources (infection, stones or cancer) (n=11). 16 patients were treated for severe hematuria (SH) requiring continuous bladder irrigation (CBI) (age 79.8±8.8, Charlson comorbidity index (CCI) 5.8±2.5, prostate gland volume (PGV) 326±171mL). 39 patients had gross hematuria (GH), but were embolized to treat urinary retention (17 patients: age 76.7±9.0, CCI 4.1±1.7, PGV 191±79mL), or lower urinary tract symptoms (22 patients: age 74.0±8.2, CCI 3.8±1.6, PGV 232±149mL). Follow-up occurred at 1, 3, 6, 12, 24, and 36 months. Adverse events were recorded using Clavien-Dindo classification. RESULTS: 55 patients were included for study (no technical failures). 13/16 (81%) SH patients had CBI stopped 2-3 days after PAE and remained free of gross hematuria (mean follow-up=500±501 days). 2 (13%) SH patients had recurrent hematuria requiring prostatic fulguration 52 and 60 days after PAE. 1 patient had recurrent hematuria 165 days later from new bladder tumor. 34/37 (92%) GH patients remained free of gross hematuria after PAE (mean follow-up=306-±234 days). There were 2 deaths <30 days after PAE (1 from unrelated warfarin toxicity, 1 from urosepsis in an immunocompromised stage 4 cancer patient). There were 7 (13%) grade 2 urinary infections and 5 (9%) self-limited grade 1 adverse events. 26/29 (89%) patients with chronic catheters were successfully voiding within 2 months after PAE. CONCLUSIONS: For patients with severe hematuria requiring CBI or gross hematuria caused by BPH, PAE is a safe, effective, and durable treatment. Embolization decreases glandular blood flow to stop bleeding, but also causes necrosis and shrinkage that relieves bladder outlet obstruction. (Figure Presented).

Cite

CITATION STYLE

APA

Ayyagari*, R., Powell, T., Chapiro, J., Staib, L., Bhatia, S., Chai, T., … Devito, R. (2019). PD24-06 PROSTATIC ARTERY EMBOLIZATION TO TREAT GROSS HEMATURIA ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 3-YEAR OUTCOMES. Journal of Urology, 201(Supplement 4). https://doi.org/10.1097/01.ju.0000555953.14265.78

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free